

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-6. (Canceled)

7. (Currently amended) A method of ~~treating~~ reducing a bacterial population:
in a subject in need of said treatment, said method comprising administering a
therapeutically effective amount of a composition of ~~Claim 5~~; or
~~in a subject, said method comprising administering a prophylactically effective~~
~~amount of a composition of Claim 5~~ comprising an isolated phage tail that inhibits growth of a
target bacterium, thereby reducing the growth of the bacterial population.

8. (Currently amended) The method of Claim 7, wherein:
~~said bacterial infection is caused by said target bacterium;~~
said subject is a human;
said subject is a primate, a food, work, display, or a companion animal;
said target bacterium is Escherichia, Staphylococcus, Pseudomonas, or
Streptococcus;
said method further comprises administering a second therapeutic or antimicrobial
agent, including administering systemically, parenterally, orally, topically, or by inhalation,
catheter, or drain tube;
said method results in a relative decrease in said population of at least 10-1000
fold; or
said method results in a decrease in detectability of said population by at least 5-
50 fold.

9-10. (Canceled)

11. (Currently amended) A method of ~~using a pharmaceutical composition of Claim 9 to treat~~ treating a bacterial infection in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of ~~said a pharmaceutical composition comprising an isolated phage tail, wherein said isolated phage tail inhibits growth of a target bacterium, thereby treating the bacterial infection.~~

12. (Original) The method of Claim 11, wherein:
said subject is a human;
said subject is a primate, a food, work, display, or companion animal;
said pharmaceutical composition is administered systemically, parenterally, orally, topically, or by inhalation, catheter, or drain tube; or
said pharmaceutical composition is administered in combination with a second therapeutic or anti-bacterial agent, e.g., an anti-microbial, inflammatory, or anti-inflammatory agent.

13-21. (Canceled)

22. (Currently amended) A method of treating a bacterial colonization in a eukaryote experiencing colonization by ~~said a target bacterium~~, said method comprising administering ~~a composition of Claim 20 to said eukaryote~~ a defined dose therapeutic anti-bacterial composition comprising an isolated phage tail, thereby treating said bacterial colonization.

23. (Original) The method of Claim 22, wherein:
said eukaryote is a mammal, including a primate;
said eukaryote is a food, work, display, or companion animal;
said target bacterium is a pathogenic, nosocomial, or pyogenic bacterium;
said target bacterium is an Escherichia, Staphylococcus, Pseudomonas, or Streptococcus bacterium;

said composition is administered systemically, parenterally, orally, topically, or by inhalation, catheter, or drain tube;

said colonization has already been treated with an anti-microbial or antibiotic;

said colonization has been diagnosed to be susceptible to the selected composition; or

said eukaryote is also inoculated with another bacterium to replace said target bacterium.

24-25. (Canceled)